TAS-205, targeting hematopoietic prostaglandin D synthase, showed no significant efficacy in improving time to rise in DMD patients over 52 weeks. The REACH-DMD trial was a placebo-controlled, ...
The prospective French participitation to IDEA (International Duration Evaluation of Adjuvant Chemotherapy) study in stage III colon cancer: Patients’ characteristics and safety analysis of 3 versus 6 ...
Early clinical trials conducted primarily in Japan have shown that TAS-102, an oral agent that combines trifluridine and tipiracil hydrochloride, was effective in the treatment of refractory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results